NCT04395859View on ClinicalTrials.gov

Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents

CompletedOBSERVATIONAL
Enrollment

233

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

December 15, 2021

Study Completion Date

February 15, 2022

Conditions
Age Related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Interventions
PROCEDURE

Questionnaire

At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment

OTHER

Data collection up to 1 year

Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications

Trial Locations (4)

75019

Fondation Adolphe de Rothschild, Paris

Unknown

Centre Pôle Vision du val d'Ouest, Écully

Hôpital Lariboisière, Paris

Centre ophtalmologique Maison Rouge, Strasbourg

All Listed Sponsors
lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

NCT04395859 - Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents | Biotech Hunter | Biotech Hunter